Rep. Val T. Hoyle Sells Elanco Animal Health Incorporated (NYSE:ELAN) Shares

Key Points

• Representative Val T. Hoyle disclosed the sale of shares in Elanco Animal Health (NYSE:ELAN) worth between $1,001 and $15,000 from her FIDELITY ROLLOVER IRA account on September 23rd.
• Elanco Animal Health stock experienced a 1.5% decline on a recent trading day, with shares trading at $19.77, having a market capitalization of $9.82 billion.
• Wall Street analysts maintain a consensus rating of "Moderate Buy" for Elanco Animal Health, with predictions for earnings per share to reach 0.91 for the current fiscal year.

Representative Val T. Hoyle (D-Oregon) recently sold shares of Elanco Animal Health Incorporated NYSE: ELAN. In a filing disclosed on October 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Elanco Animal Health stock on September 23rd. The trade occurred in the Representative's "FIDELITY ROLLOVER IRA" account.

Representative Val T. Hoyle also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Marriott International NASDAQ: MAR on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Transdigm Group NYSE: TDG on 9/23/2025.
• Sold $1,001 - $15,000 in shares of H&R Block NYSE: HRB on 9/23/2025.
• Sold $1,001 - $15,000 in shares of NIKE NYSE: NKE on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Bank of New York Mellon NYSE: BK on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Cisco Systems NASDAQ: CSCO on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Capital One Financial NYSE: COF on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Pentair NYSE: PNR on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Heico NYSE: HEI.A on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Target NYSE: TGT on 9/23/2025.

Elanco Animal Health Stock Down 1.5%

Shares of NYSE:ELAN traded down $0.30 during midday trading on Friday, hitting $19.77. 4,599,679 shares of the stock were exchanged, compared to its average volume of 5,623,531. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $21.76. The business's fifty day simple moving average is $18.35 and its two-hundred day simple moving average is $14.40. The company has a market capitalization of $9.82 billion, a PE ratio of 22.99, a P/E/G ratio of 3.70 and a beta of 1.65.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.19 billion. During the same period last year, the company earned $0.30 earnings per share. Elanco Animal Health's quarterly revenue was up 4.8% compared to the same quarter last year. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ELAN has been the subject of several recent research reports. UBS Group increased their price objective on Elanco Animal Health from $18.00 to $19.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Stifel Nicolaus increased their price objective on Elanco Animal Health from $18.00 to $23.00 and gave the stock a "buy" rating in a report on Wednesday, September 24th. Leerink Partnrs upgraded Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 17th. Weiss Ratings restated a "hold (c-)" rating on shares of Elanco Animal Health in a report on Wednesday. Finally, Zacks Research upgraded Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $19.14.

Hedge Funds Weigh In On Elanco Animal Health

Institutional investors have recently bought and sold shares of the stock. Allworth Financial LP grew its position in shares of Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company's stock valued at $25,000 after purchasing an additional 2,090 shares during the last quarter. NBC Securities Inc. acquired a new stake in shares of Elanco Animal Health in the first quarter valued at about $40,000. First Horizon Advisors Inc. grew its position in shares of Elanco Animal Health by 184.3% in the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company's stock valued at $53,000 after purchasing an additional 2,414 shares during the last quarter. Wealthquest Corp acquired a new stake in shares of Elanco Animal Health in the first quarter valued at about $56,000. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of Elanco Animal Health by 261.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company's stock valued at $58,000 after purchasing an additional 2,922 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

About Representative Hoyle

Val Hoyle (Democratic Party) is a member of the U.S. House, representing Oregon's 4th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. Hoyle (Democratic Party) is running for re-election to the U.S. House to represent Oregon's 4th Congressional District. She declared candidacy for the 2026 election. Val Hoyle was born in California and lives in Springfield, Oregon. Hoyle graduated from Merrimack High School. She earned a B.A. in political science from Emmanuel College in 1992. Her career experience includes working as a director at United Way of Lane County, a policy fellow at Wayne Morse Center for Law and Politics, and a commissioner at the Oregon Bureau of Labor and Industries. Hoyle has also worked in domestic and international sales, as well as manufacturing distribution.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.